50.56
+3(+6.31%)
Currency In USD
| Previous Close | 47.56 |
| Open | 48.58 |
| Day High | 53.41 |
| Day Low | 48.02 |
| 52-Week High | 53.41 |
| 52-Week Low | 1.4 |
| Volume | 84,064 |
| Average Volume | 124,190 |
| Market Cap | 745.9M |
| PE | -16.47 |
| EPS | -3.07 |
| Moving Average 50 Days | 43.73 |
| Moving Average 200 Days | 24.21 |
| Change | 3 |
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
GlobeNewswire Inc.
Dec 03, 2024 9:01 PM GMT
WATERTOWN, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”) a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the acti
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
GlobeNewswire Inc.
Nov 26, 2024 9:01 PM GMT
WATERTOWN, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (Tectonic), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activ
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
GlobeNewswire Inc.
Nov 11, 2024 10:00 AM GMT
Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and impact on renal plasma flow (“RPF”)TX45 showed a favorable safety profile, with